Pharmaceutical, clinical, and immunohistochemical studies of metformin hydrochloride topical hydrogel for wound healing application

Tawfeek, Hesham M.; Abou-Taleb, Doaa A E; Badary, Dalia M.; Ibrahim, Mohamed F.; Abdellatif, Ahmed A. H.

doi:10.1007/s00403-019-01982-1

Cited by 26 publications

(17 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metformin was also able to restore basal levels of thrombospondin 1, an endogenous antiangiogenic mediator known to be involved in vascular complications in diabetes [81]. Notably, metformin was effective in accelerating wound healing by improving epidermis, hair follicles, and collagen deposition also when applied topically in young rats undergoing an excision wound [82,83] and confirmed its efficacy also in patients carrying non-healing lower limb traumatic wounds or ulcers [82]. The clinical response observed was ascribed to increased production of TGFβ in the wounded area, a growth factor known to affect angiogenesis, inflammatory reaction, granulation tissue formation, ECM deposition, re-epithelization and remodeling, thus promoting the healing process [84].…”

Section: Metforminmentioning

confidence: 99%

The Treatment of Impaired Wound Healing in Diabetes: Looking among Old Drugs

et al. 2020

View full text Add to dashboard Cite

Chronic wounds often occur in patients with diabetes mellitus due to the impairment of wound healing. This has negative consequences for both the patient and the medical system and considering the growing prevalence of diabetes, it will be a significant medical, social, and economic burden in the near future. Hence, the need for therapeutic alternatives to the current available treatments that, although various, do not guarantee a rapid and definite reparative process, appears necessary. We here analyzed current treatments for wound healing, but mainly focused the attention on few classes of drugs that are already in the market with different indications, but that have shown in preclinical and few clinical trials the potentiality to be used in the treatment of impaired wound healing. In particular, repurposing of the antiglycemic agents dipeptidylpeptidase 4 (DPP4) inhibitors and metformin, but also, statins and phenyotin have been analyzed. All show encouraging results in the treatment of chronic wounds, but additional, well designed studies are needed to allow these drugs access to the clinics in the therapy of impaired wound healing.

show abstract

Section: Metforminmentioning

confidence: 99%

The Treatment of Impaired Wound Healing in Diabetes: Looking among Old Drugs

et al. 2020

View full text Add to dashboard Cite

show abstract

“…5 The effects of metformin on wound healing in different studies were controversial. Tawfeek et al 6 evaluated the potential wound healing effects of metformin hydrochloride hydrogel (6 mg/g gel) in rats. Another study performed in the mice model showed that metformincontained hydrogel dressing increased wound healing rate and angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

Metformin ointment may relieve hypertrophic and keloid scars

Hedayatyanfard,

Niazi,

Hesami

et al. 2023

Aust J Dermatology

View full text Add to dashboard Cite

Various factors are involved in keloid and hypertrophic scar formation. Keloid and hypertrophic scars differ in incidence, location, histology and treatment. Previous research showed that metformin has antioxidant and anti-inflammatory properties, antiageing and antitumour, and cardioprotective and neuroprotective effects. 1 Here we conducted a clinical trial study to investigate the metformin topical ointment for treating hypertrophic scar and keloid and compared it with the placebo. MATERIALS AND METHODSA randomized, blinded, clinical trial study was conducted on hypertrophic scar and keloid patients between 2021 and 2022 in 15 Khordad Hospital (Tehran, Iran). Exclusion criteria were: diabetes, lactation and pregnancy, bleeding and discharge in the scar tissue site, chemotherapy, allergy history to metformin or placebo and history of scar treatment in the last 2 months. All patients were randomly assigned to receive metformin or placebo ointments. Metformin hydrochloride powder dissolved in water and dispersed in the base ointment (lanolin, fatty acids, cholesterol, wax) at a concentration of 0.5% (w/v). Placebo ointment was prepared similarly without metformin hydrochloride powder. The patients used the topical metformin ointment 0.5% (w/v) and placebo twice a day for 3 months and we used the Vancouver Scar Scale (VSS) (Table 1) before and during the study for assessment of the scars which have four variables: Vascularity (normal = 0, pink = 1, red = 2 and purple = 3), pigmentation (normal = 0, hypopigmentation = 1 and hyperpigmentation = 2), pliability (normal = 0, supple = 1, yielding = 2, firm = 3, ropes = 4 and contracture = 5) and height (flat = 0, <2 mm = 1, 2-5 mm = 2 and >5 mm = 3). Furthermore, all patients were followed for 6 months to evaluate the effects of treatment. Written consent was obtained from all patients in this clinical trial study, and a physician evaluated patients' scars.

show abstract

“…71 Though these are easily accessible and inexpensive reagents but show cytotoxicity and immunological responses. 18 The ionic cross-linkers including potassium bicarbonate, 64 sodium hexameta phosphate, 65 ferric chloride, 66 Ca 2+ , 68 and sodium hydroxide 69 produce nonpermanent cross-linking and formed by reversible links, limited by mechanical instability of the hydrogel. In the present study, maleic acid was utilized as a crosslinker, which is novel and nontoxic to human blood cells (hemolytic ratio 3.733%).…”

Section: Comparative Studiesmentioning

confidence: 99%

Chitosan based hybrid superabsorbent for controlled drug delivery application

Medha,

Sethi

2024

Biotechnology Progress

View full text Add to dashboard Cite

In the present study, a hybrid chitosan‐alginate superabsorbent is prepared using maleic acid as a cross‐linker and acrylamide as a grafting agent using the free radical mechanism. The composite hydrogel shows good swelling capacity along with hemocompatibility and biocompatibility and hence it is utilized as a drug delivery device. The characterization techniques including x‐ray diffraction, Fourier transform infrared, x‐ray photoelectron spectroscopy, and thermal analysis indicate the successful synthesis of stable hydrogel with rich functionalities. Metformin hydrochloride is used as a model drug which is used to treat diabetes. The drug encapsulation is done using the swelling diffusion method after the synthesis of hydrogel. The release of metformin from the drug‐loaded hydrogel at physiological pH highlights the role of non‐covalent interactions between the drug and hydrogel. In vitro release studies of Metformin from the drug‐loaded hydrogel show higher release profiles at intestinal pH (7.4) compared to stomach pH (1.2). The observed cumulative release is 82.71% at pH 7.4 and 45.67% at pH 1.2 after 10 h. Brunauer–Emmett–Teller analysis reveals the effect of surface area, pore size, and pore volume of hydrogel on the drug release. The drug release from the hybrid chitosan‐alginate hydrogel is found to be more sustained in comparison to the pure chitosan hydrogel. For the present drug delivery system, the swelling‐controlled release is found to be more dominating than the pH‐controlled release. The synthesized hydrogel can be successfully employed as a potential drug delivery system for controlled drug delivery.

show abstract

Pharmaceutical, clinical, and immunohistochemical studies of metformin hydrochloride topical hydrogel for wound healing application

Cited by 26 publications

References 37 publications

The Treatment of Impaired Wound Healing in Diabetes: Looking among Old Drugs

The Treatment of Impaired Wound Healing in Diabetes: Looking among Old Drugs

Metformin ointment may relieve hypertrophic and keloid scars

Chitosan based hybrid superabsorbent for controlled drug delivery application

Contact Info

Product

Resources

About